STCube Presents New Immuno-Oncology Treatment Strategy for Colorectal Cancer at ASCO GI

STCube will participate in various pharmaceutical and bio-related events next year.

STCube announced on the 27th that it will attend the 'JP Morgan Healthcare Conference' held from January 13 to 16 next year. It will also attend the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI), which will be held for three days starting on the 23rd of the same month.

At ASCO GI 2025, two research abstracts on Nelmastovat (hSTC810) have been accepted for poster presentations. Nelmastovat is an immune checkpoint inhibitor candidate targeting BTN1A1.

STCube's Chief Scientific Officer (CSO), Yoo Seung-han, will present on "Expression of BTN1A1 in Colorectal Cancer: Impact on Immunotherapy and Patient Stratification." This research suggests that BTN1A1-targeted therapy can enhance the response to immune checkpoint inhibitors in colorectal cancer.

Professor Lee Soo-hyun of Korea University Anam Hospital's Department of Oncology, who is leading the investigator-initiated Phase 1b/2 clinical trials of Nelmastovat in colorectal cancer, will present on the topic of a Phase 1b clinical trial combining Nelmastovat and capecitabine in metastatic colorectal cancer patients resistant or intolerant to oxaliplatin- and irinotecan-based chemotherapy.

An STCube representative said, "Through ASCO GI, we will officially present the results of the investigator-initiated Phase 1b study of Nelmastovat in colorectal cancer at an international conference," adding, "We plan to present the safety, efficacy results, and promising anticancer activity observed in 12 patients with metastatic colorectal cancer who have undergone third-line or later treatments."

This content was produced with the assistance of AI translation services.